PE20231934A1 - COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF - Google Patents

COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF

Info

Publication number
PE20231934A1
PE20231934A1 PE2023001497A PE2023001497A PE20231934A1 PE 20231934 A1 PE20231934 A1 PE 20231934A1 PE 2023001497 A PE2023001497 A PE 2023001497A PE 2023001497 A PE2023001497 A PE 2023001497A PE 20231934 A1 PE20231934 A1 PE 20231934A1
Authority
PE
Peru
Prior art keywords
compositions
methods
escherichia coli
coli
derived
Prior art date
Application number
PE2023001497A
Other languages
Spanish (es)
Inventor
Annaliesa Sybil Anderson
Laurent Oliver Chorro
Robert George Konrad Donald
Jacqueline Marie Lypowy
Rosalind Pan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20231934A1 publication Critical patent/PE20231934A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invencion se relaciona con composiciones que incluyen un polipeptido derivado de E. coli o un fragmento del mismo; y moleculas de O-polisacarido modificadas derivadas de lipopolisacaridos de E. coli y conjugados de los mismos y metodos de uso de los mismosThis invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof and methods of use thereof

PE2023001497A 2020-10-27 2021-10-25 COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF PE20231934A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063106077P 2020-10-27 2020-10-27
US202163144058P 2021-02-01 2021-02-01
US202163254195P 2021-10-11 2021-10-11
PCT/IB2021/059820 WO2022090893A2 (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof

Publications (1)

Publication Number Publication Date
PE20231934A1 true PE20231934A1 (en) 2023-12-01

Family

ID=78500672

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001497A PE20231934A1 (en) 2020-10-27 2021-10-25 COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF

Country Status (11)

Country Link
EP (1) EP4237428A2 (en)
JP (1) JP2023546615A (en)
KR (1) KR20230096033A (en)
AU (1) AU2021368151A1 (en)
CA (1) CA3199610A1 (en)
CO (1) CO2023005372A2 (en)
IL (1) IL302362A (en)
MX (1) MX2023004912A (en)
PE (1) PE20231934A1 (en)
TW (1) TW202227467A (en)
WO (1) WO2022090893A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111907A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2055785T3 (en) 1989-01-17 1994-09-01 Eniricerche Spa SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
ATE128628T1 (en) 1990-08-13 1995-10-15 American Cyanamid Co FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE.
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
ATE178907T1 (en) 1992-05-06 1999-04-15 Harvard College RECEPTOR-BINDING REGION OF DIPHTHERIAL TOXIUS
DK0761231T3 (en) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccine containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2231770T3 (en) 1993-03-05 2005-05-16 Wyeth Holdings Corporation NEW PLASMIDS FOR THE PRODUCTION OF CRM PROTEIN AND DIFTERIC TOXIN.
KR100310510B1 (en) 1993-03-23 2002-07-04 장 스테판느 Vaccine composition containing 3-0-deacetylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE420171T1 (en) 1994-07-15 2009-01-15 Univ Iowa Res Found IMMUNOMODULATORY OLIGONUCLEOTIDES
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
JP2001513776A (en) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2298316T3 (en) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999051259A2 (en) 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CN1296416A (en) 1998-04-09 2001-05-23 史密丝克莱恩比彻姆生物有限公司 Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PL201482B1 (en) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Adjuvant systems and vaccines
AU776828B2 (en) 1998-12-21 2004-09-23 Medimmune, Llc Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
CZ302790B6 (en) 1998-12-23 2011-11-09 Id Biomedical Corporation Isolated polynucleotide, vector, host cell, production process, isolated polypeptide, chimeric polypeptide, vaccine and use thereof
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
PL203951B1 (en) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Vaccines
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU7038101A (en) 2000-06-20 2002-01-02 Shire Biochem Inc Streptococcus antigens
AU2001271907A1 (en) * 2000-07-07 2002-01-21 Medimmune, Inc. FimH adhesin proteins and methods of use
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
CA2518669C (en) 2003-03-13 2014-07-29 Glaxosmithkline Biologicals S.A. Purification process
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2008506683A (en) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド Methods and compositions for inducing innate immune responses
KR100958505B1 (en) 2004-07-18 2010-05-17 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1868645B1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101784282B (en) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
BRPI1014494A2 (en) 2009-04-30 2016-08-02 Coley Pharm Group Inc pneumococcal vaccine and its uses
MX363511B (en) 2012-08-16 2019-03-26 Pfizer Glycoconjugation processes and compositions.
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CN106062203B (en) * 2013-10-11 2020-08-07 葛兰素史密丝克莱恩生物有限公司 Method for host cell modification
EP3193918A4 (en) * 2014-09-18 2018-06-20 University of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
CN111372946A (en) 2017-02-17 2020-07-03 隆萨有限公司 Multi-site specific integration cells of difficult to express proteins
GB201711635D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4051696A1 (en) * 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3173729A1 (en) * 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof

Also Published As

Publication number Publication date
WO2022090893A3 (en) 2022-06-09
CA3199610A1 (en) 2022-05-05
IL302362A (en) 2023-06-01
MX2023004912A (en) 2023-05-16
CO2023005372A2 (en) 2023-05-19
EP4237428A2 (en) 2023-09-06
TW202227467A (en) 2022-07-16
AU2021368151A1 (en) 2023-06-01
KR20230096033A (en) 2023-06-29
JP2023546615A (en) 2023-11-06
AU2021368151A8 (en) 2023-06-22
WO2022090893A2 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CO2021003036A2 (en) Fused Ring Compounds
CO2023005372A2 (en) Escherichia coli compositions and methods thereof
CL2018001941A1 (en) Anti tgfbeta 2 antibodies
CO2022000029A2 (en) Prevotella preparations and treatment of chronic obstructive pulmonary disease (COPD) and other lung conditions
CL2020001944A1 (en) Fc il-22 fusion proteins and methods of use.
CL2019002876A1 (en) Synthesis of triterpene-saponin, intermediates and adjuvant combinations.
ECSP19057403A (en) THERAPEUTIC USES OF AN INSECT POWDER
CO2022001210A2 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MX2022005252A (en) Escherichia coli compositions and methods thereof.
CO2022011991A2 (en) Esquerichia coli compositions and their methods
PE20211095A1 (en) ESCHERICHIA COLI COMPOSITIONS AND METHODS OF THEM
BR112022001016A2 (en) PRODUCTION METHODS OF AFLIBERCEPTE
CO2021010786A2 (en) Inactivated apxia, apxiia, and apxiiia toxins
CO2021000147A2 (en) Agricultural composition
CL2020003034A1 (en) Tlr7 agonists
CL2023000146A1 (en) Viscosity-reducing excipients and combinations thereof for highly concentrated protein formulations
EA202092335A1 (en) COMPOSITIONS BASED ON ERENUMAB AND WAYS OF THEIR APPLICATION
CO2020013557A2 (en) Variants of lfa3 and compositions and uses thereof
BR112022013339A2 (en) KV3 MODULATORS
BR112018068522A2 (en) new proteins derived from alpha-1-microglobulin and their use
EA202092327A1 (en) LFA3 OPTIONS AND THEIR COMPOSITIONS AND APPLICATIONS
JP1728301S (en) ottoman
JP1728302S (en) ottoman
CO2022010244A2 (en) Anti-e-selectin antibodies, compositions and methods of use
BR112022005952A2 (en) ORAL HYGIENE COMPOSITIONS AND METHODS OF USE